This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of 
receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of 
breathing, and cognitive abilities related to 
memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's 
disease, 
schizophrenia, respiratory depression, sleep apneas, 
attention deficit hyperactivity disorder and affective or 
mood disorders, and in disorders wherein a deficiency in 
neurotrophic factors is implicated, as well as in disorders of 
respiration such as overdose of an 
alcohol, an 
opiate, an 
opioid, a 
barbiturate, an 
anesthetic, or a nerve 
toxin, or where the respiratory depression results form a medical condition such as 
central sleep apnea, 
stroke-induced 
central sleep apnea, 
obstructive sleep apnea, congenital hypoventilation syndrome, 
obesity hypoventilation syndrome, sudden infant death syndrome, 
Rett syndrome, 
spinal cord injury, 
traumatic brain injury, Cheney-Stokes 
respiration, Ondines curse, Prader-Willi'
s syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.